Neurodegenerative Dysfunction-Centered Sage Therapeutics Inventory Falls On Disappointing Parkinson’s Knowledge – Sage Therapeutics (NASDAQ:SAGE)

Wednesday, Sage Therapeutics Inc SAGE introduced topline outcomes from the PRECEDENT Part 2 research of dalzanemdor (SAGE-718) in individuals with delicate cognitive impairment in Parkinson’s Illness. 

The PRECEDENT Examine didn’t meet its major endpoint of demonstrating a statistically vital distinction from baseline in individuals handled with once-daily dalzanemdor versus placebo on the Wechsler Grownup Intelligence Scale Fourth Version-IV (WAIS-IV) Coding Check rating at Day 42. 

WAIS-IV is probably the most superior grownup measure of cognitive capacity.

Dalzanemdor (SAGE-718) was typically well-tolerated, and no new security alerts had been noticed.

48 individuals skilled treatment-emergent opposed occasions (TEAEs). The overwhelming majority of TEAES had been delicate to average in severity.

“We’re dissatisfied by the outcomes of the Part 2 PRECEDENT research given the numerous burden of delicate cognitive impairment on individuals and households affected by Parkinson’s Illness,” mentioned Barry Greene, Chief Govt Officer at Sage Therapeutics. 

Analyses didn’t counsel significant variations versus placebo within the different exploratory endpoints, reminiscent of SCOPA-Cog, a measure for assessing cognitive operate.

Primarily based on the info, the corporate doesn’t plan to develop dalzanemdor (SAGE-718) additional in Parkinson’s Illness. 

The corporate expects the next milestones for the dalzanemdor (SAGE-718) Part 2 medical growth program in 2024:

• Topline information from the SURVEYOR Examine in Huntington’s illness cognitive impairment in mid-2024.
•  Topline information from LIGHTWAVE Examine in individuals with delicate cognitive impairment and delicate dementia in Alzheimer’s illness in late 2024.
•  Topline information from the DIMENSION Examine in individuals with Huntington’s illness cognitive impairment in late 2024.

Worth Motion: SAGE shares are down 23.80% at $11.91 on the final verify Wednesday.